Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

Journal of Immunotherapy

Volumn 35, Issue 8, 2012, Pages 615-620

  Pilon Thomas, Shari ^a   Kuhn, Lisa ^a   Ellwanger, Sabine ^a   Janssen, William ^a   Royster, Erica ^a   Marzban, Suroosh ^a   Kudchadkar, Ragini ^a   Zager, Jonathan ^a   Gibney, Geoffrey ^a   Sondak, Vernon K ^a   Weber, Jeffrey ^a   Mulé, James J ^a   Sarnaik, Amod A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

adoptive cell therapy; lymphodepletion; metastatic melanoma; tumorinfiltrating lymphocytes

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ADULT; AGED; ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEPIGMENTATION; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HEMORRHAGIC CYSTITIS; HUMAN; LYMPHOCYTOPENIA; MALE; METASTATIC MELANOMA; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; UVEITIS; VITILIGO;

ADULT; AGED; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOPENIA; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84866635452     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31826e8f5f     Document Type: Article

References (15)

1. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23: 2346-2357. (Pubitemid 46218728)
2. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318-1321. (Pubitemid 16002234)
4. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-4557.
5. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-Term survival update. Cancer J Sci Am. 2000;6: S11-S14.
6. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477-3482. (Pubitemid 32730084)
7. Friedman KM, Prieto PA, Devillier LE, et al. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother. 2012;35:400-408.
8. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
10. Li Y, Liu S, Hernandez J, et al. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol. 2010;184: 452-465.
11. Hernandez-Chacon JA, Li Y, Wu RC, et al. Co-stimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances anti-Tumor effector function. J Immunother. 2011;34:236-250.
12. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47-55. (Pubitemid 27304846)
13. Sarnaik A, Bilotto A, Jure-Kunkel M, et al. Costimulatory effect of agonistic 4-1BB antibody on proliferation and effector phenotype of tumor-infiltrating lymphocytes in melanoma. J Clin Oncol. 2012;30(suppl): abstr 2511.
14. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175:7046-7052. (Pubitemid 41598952)
15. Pilon-Thomas SA, Mackay A, Vohra N, et al. Blockade of programmed death ligand-1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol. 2010;184:3442-3449.